NCT05189288View on ClinicalTrials.gov

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

March 12, 2022

Study Completion Date

April 15, 2022

Conditions
Chronic Hepatitis b
Interventions
DRUG

D418 Tab.

1T

DRUG

CKD-388 Tab.

1T

Trial Locations (1)

Unknown

H plus Yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY